ReviewCurrent allergy and asthma reports2026
Biologics in Pediatric Asthma: Controlling Symptoms, Maintaining Safety, and Improving Outcomes.
Review in Current allergy and asthma reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewBiologic therapies have transformed treatment for children and adolescents with moderate-to-severe asthma. This review summarizes recent evidence regarding FDA-approved biologics for pediatric asthma—omalizumab, mepolizumab, benralizumab, dupilumab, and tezepelumab—with focus on efficacy, safety, and practical considerations for clinical use. RECENT
findingsThese agents consistently demonstrate reductions in exacerbations, improved lung function, and/or enhanced quality of life. Long-term extension studies have reinforced favorable safety profiles, with low incidence of serious adverse events. Biomarkers such as blood eosinophils, FeNO, and IgE can guide biologic selection, along with presence of coexisting atopic conditions. Ultimately, optimal biologic choice depends on phenotype, biomarker profiles, and patient-specific needs. Pediatric evidence remains limited regarding criteria and strategies for biologic discontinuation. Biologics provide durable benefit and safety in pediatric asthma. Incorporating biomarkers, comorbidities, evolving discontinuation guidance, and shared decision-making with families is essential to optimize therapy and personalize care.
Indexed as
Identifiers
41636912What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.